Skip to content

Anti KU Antibodies and Its Relationship With Systemic Lupus Erythematosus

Anti KU Antibodies and Its Relationship With Systemic Lupus Erythematosus

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05900232
Enrollment
60
Registered
2023-06-12
Start date
2023-05-15
Completion date
2023-11-01
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Brief summary

systemic lupus Erythematosus (SLE) is a multi system autoimmune disorder abroad spectrum of clinical presentations. Diagnosis of SLE depending on Systemic Lupus International Collaborating Clinics (SLICC) Criteria. SLICC Criteria requires either that a patient satisfy at least 4 of 17 Criteria including at least 1 of 11 clinical criteria and 1 of 6 immunological criteria or the patient has biopsy -proven nephritis compatible with SLE in the presence of antinuclear antibodies (ANA)or anti\_double stranded DNA (dsDNA) antibodies. Anti\_KU antibodies included in (ANA), reported in many autoimmune disorders like SLE,Sjogren syndrome, idiopathic lung fibrosis and myositis. So the aim of the work is to determine the relationship between Anti\_KU antibodies and SLE manifestations.

Interventions

DIAGNOSTIC_TESTAnti _KU antibodies

aim of the work is to determine the relationship between Anti\_Ku antibodies and SLE manifestations the study will include 60 SLE cases diagnosed by SLICC criteria and the activity of SLE will be calculated by SELDAI criteria, which is tool composed of 24 clinical and laboratory variables.

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
17 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* all patients will fulfill the Systemic Lupus International Clinics(SLICC) classification criteria for Systemic Lupus Erythematosus.

Exclusion criteria

* any patient with any collagen disease other than SLE

Design outcomes

Primary

MeasureTime frameDescription
Anti KU antibodies and its relationship with Systemic Lupus Erythematosus manifestations6 monthsthe study will evaluate the titre of Anti KU antibodies which is positive or negative in one patient and on the other side what is the manifestation of SLE that found in the same patient if the Anti KU Antibodies titre is positive

Countries

Egypt

Contacts

Primary ContactNehal A Ahmed, resident
nehal011209@med.sohag.edu.eg01145379717
Backup ContactOsama S Daifallah, Associate Professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026